Aurinia Pharmaceuticals Inc (AUPH) - Total Liabilities
Based on the latest financial reports, Aurinia Pharmaceuticals Inc (AUPH) has total liabilities worth $170.26 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Aurinia Pharmaceuticals Inc to assess how effectively this company generates cash.
Aurinia Pharmaceuticals Inc - Total Liabilities Trend (1998–2025)
This chart illustrates how Aurinia Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Check Aurinia Pharmaceuticals Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Aurinia Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Aurinia Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kunshan Kersen Science & Tech
SHG:603626
|
China | CN¥3.18 Billion |
|
China Nonferrous Metal Industry’s Foreign Engineering and Construction Co Ltd
SHE:000758
|
China | CN¥13.69 Billion |
|
Sigdo Koppers
SN:SK
|
Chile | CL$2.73 Billion |
|
Global Net Lease, Inc.
NYSE:GNL
|
USA | $2.68 Billion |
|
Shenzhen iN-Cube Automation Co. Ltd.
SHE:301312
|
China | CN¥226.36 Million |
|
Vohringer Home Technology Co Ltd
SHG:603226
|
China | CN¥374.32 Million |
|
JOYY Inc
NASDAQ:JOYY
|
USA | $898.33 Million |
|
ARMOUR Residential REIT Inc
NYSE:ARR
|
USA | $18.74 Billion |
Liability Composition Analysis (1998–2025)
This chart breaks down Aurinia Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Aurinia Pharmaceuticals Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aurinia Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aurinia Pharmaceuticals Inc (1998–2025)
The table below shows the annual total liabilities of Aurinia Pharmaceuticals Inc from 1998 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $170.26 Million | -1.68% |
| 2024-12-31 | $173.17 Million | +1.80% |
| 2023-12-31 | $170.11 Million | +160.00% |
| 2022-12-31 | $65.42 Million | +1.79% |
| 2021-12-31 | $64.28 Million | +14.96% |
| 2020-12-31 | $55.91 Million | +117.54% |
| 2019-12-31 | $25.70 Million | -22.79% |
| 2018-12-31 | $33.29 Million | +38.10% |
| 2017-12-31 | $24.10 Million | +14.52% |
| 2016-12-31 | $21.05 Million | +54.71% |
| 2015-12-31 | $13.60 Million | +87.07% |
| 2014-12-31 | $7.27 Million | -26.11% |
| 2013-12-31 | $9.84 Million | +56.75% |
| 2012-12-31 | $6.28 Million | -20.63% |
| 2011-12-31 | $7.91 Million | +101.05% |
| 2010-12-31 | $3.93 Million | -16.98% |
| 2009-12-31 | $4.74 Million | -74.78% |
| 2008-12-31 | $18.79 Million | +31.82% |
| 2007-12-31 | $14.25 Million | +36.12% |
| 2006-12-31 | $10.47 Million | -12.69% |
| 2005-12-31 | $11.99 Million | +33.65% |
| 2004-12-31 | $8.97 Million | +52.33% |
| 2003-12-31 | $5.89 Million | +88.80% |
| 2002-12-31 | $3.12 Million | +75.33% |
| 2001-12-31 | $1.78 Million | +47.12% |
| 2000-12-31 | $1.21 Million | +27.22% |
| 1999-12-31 | $950.74K | -60.53% |
| 1998-12-31 | $2.41 Million | -- |
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and … Read more